Affiliation: Thames Valley University
- Genotoxicity profile of fexinidazole--a drug candidate in clinical development for human African trypanomiasis (sleeping sickness)David Tweats
Drugs for Neglected Diseases Initiative, 15 Chemin Louis Dunant, Geneva CH 1202, Switzerland
Mutagenesis 27:523-32. 2012..Thus, fexinidazole does not pose a genotoxic hazard to patients and represents a promising drug candidate for HAT. Fexinidazole is expected to enter Phase II clinical trials in 2012...
- Determination of genetic toxicity and potential carcinogenicity in vitro--challenges post the Seventh Amendment to the European Cosmetics DirectiveD J Tweats
The Medical School, University of Wales Swansea, Singleton Park, SA2 8PP, UK
Mutagenesis 22:5-13. 2007..This commentary brings together ideas and approaches from several international workshops and meetings to consider these issues...
- Elevated ethyl methanesulfonate (EMS) in nelfinavir mesylate (Viracept(R), Roche): overviewAnton Pozniak
Pharmaceuticals Division, Hoffmann La Roche, Nutley, NJ, USA
AIDS Res Ther 6:18. 2009..These findings are potentially relevant to >40 marketed drugs that are mesylate salts...
- 1-Aryl-4-nitro-1H-imidazoles, a new promising series for the treatment of human African trypanosomiasisBernadette Bourdin Trunz
Drugs for Neglected Diseases Initiative, 15 Chemin Louis Dunant, 1202 Geneva, Switzerland
Eur J Med Chem 46:1524-35. 2011..Both compounds are promising leads for the treatment of human African trypanosomiasis (HAT or sleeping sickness), including the fatal stage 2 of the disease, for which new treatments are urgently needed...